EU regulator supports a label expansion of Novo Nordisk’s diabetes drug to reflect its potential to lower the risk of ...

Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and ...

LAB eN 2, the drug discovery accelerator launched by Evotec and Novo Nordisk in September 2023, has unveiled its first three ...

Thursday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has supported label update for weight-loss drug Ozempic to include kidney disease risk ...

The EMA approved a kidney disease–related label expansion for the blockbuster GLP-1 drug after a study showed reduced risk of ...

The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the ...

Wegovy and other GLP-1 medications have become extremely popular over the past few years. Novo Nordisk (which makes both ...

Market multiples for Novo Nordisk are also attractive now, especially with a forward P/E for 2025 at 28.3x. Learn more about NVO stock here.

Evotec and Novo Nordisk launched LAB eN² in September 2023 to nurture early research from academic institutions into novel therapeutics.